RT Journal Article
SR Electronic
T1 A Neuropathology Case Report of a Woman with Down Syndrome who Remained Cognitively Stable
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.01.24308050
DO 10.1101/2024.06.01.24308050
A1 Liou, Jr-Jiun
A1 Lou, Jerry
A1 Nakagiri, Jamie
A1 Yong, William
A1 Hom, Christy L.
A1 Doran, Eric W.
A1 Totoiu, Minodora
A1 Lott, Ira
A1 Mapstone, Mark
A1 Keator, David B.
A1 Brickman, Adam M.
A1 Wright, Sierra
A1 Nelson, Brittany
A1 Lai, Florence
A1 Xicota, Laura
A1 Dang, Lam-Ha T.
A1 Li, Jinghang
A1 Santini, Tales
A1 Mettenburg, Joseph M.
A1 Ikonomovic, Milos D.
A1 Kofler, Julia
A1 Ibrahim, Tamer
A1 Head, Elizabeth
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/06/03/2024.06.01.24308050.abstract
AB In this neuropathology case report, we present findings from an individual with Down syndrome (DS) who remained cognitively stable despite Alzheimer’s disease (AD) neuropathology. Clinical assessments, fluid biomarkers, neuroimaging, and neuropathological examinations were conducted to characterize her condition. Notably, her ApoE genotype was E2/3, which is associated with a decreased risk of dementia. Neuroimaging revealed stable yet elevated amyloid profiles and moderately elevated tau levels, while neuropathology indicated intermediate AD neuropathologic change with Lewy body pathology and cerebrovascular pathology. Despite the presence of AD pathology, the participant demonstrated intact cognitive functioning, potentially attributed to factors such as genetic variations, cognitive resilience, and environmental enrichment. The findings suggest a dissociation between clinical symptoms and neuropathological changes, emphasizing the complexity of AD progression in DS. Further investigation into factors influencing cognitive resilience in individuals with DS, including comorbidities and social functioning, is warranted. Understanding the mechanisms underlying cognitive stability in DS could offer insights into resilience to AD neuropathology in people with DS and in the general population and inform future interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the NIH/NIA U19AG068054, P30AG066519, U01AG051412, RF1AG079519, P01AG025204, P01AG014449, and NIH/NICHD R01HD065160.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Committee for Oversight of Research and Clinical Training Involving Decedents of the University of Pittsburgh and the University of California, Irvine gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscriptAβ40amyloid beta 40Aβ42amyloid beta 42ADAlzheimer’s diseaseApoEapolipoprotein EAPPamyloid precursor proteinBMIbody mass indexCAAcerebral amyloid angiopathyCERADConsortium to Establish a Registry for Alzheimer’s diseaseCScognitively stableCSFcerebrospinal fluidDLDDementia Questionnaire for People with Learning DisabilitiesDSDown syndromeDSMSEDown Syndrome Mental Status ExaminationFBPflorbetapirFSIQfull scale IQGFAPglial fibrillary acidic proteinKBIT-2Kaufman Brief Intelligence Test, 2nd EditionMCImild cognitive impairmentMRImagnetic resonance imagingNfLneurofilament lightPETpositron emission tomography pTau181: phosphorylated tau 181RADD-2Rapid Assessment for Developmental Disabilities, 2nd EditionROIregion of interestSUVRstandardized uptake value ratiotTautotal tauWAIS-RWechsler Adult Intelligence Scale, Revised Edition